Explore 3 Stock Ideas & Industry Insights Download Free Report

Covalon Technologies Ltd.

Company price
4.06 CAD -0.20 ( 4.69%)
Last update at 2026-11-05T18:35:00Z
VOLUME
13785
Market Cap
53.86M
P/E
65.00

Momentum Score

…

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, perioperative dressings, silicone dressings, vascular access line guards, and wound dressings; and surgical, peri-operative, and infection management products. It sells its products directly and through independent distributors under the ColActive, ColActive PLUS, CovaWound, CovaView, CovaClear IV, IV Clear, SurgiClear, MediClear, and VALGuard brands. The company serves health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.06
Low
4.33
High
52 Week Price Range
1.55
Low
2.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Covalon Technologies Ltd. develops and commercializes medical technologies focused on infection prevention, wound care and surgical sealants for hospitals and device manufacturers. Long-term growth drivers include clinical adoption and market access for its surface-coating and dressing platforms, growing demand for products that reduce healthcare-associated infections, and potential licensing or distribution arrangements that could support scale.

Key risks include uncertain regulatory approvals and commercialization execution, limited financial and liquidity resources common to small-cap medical developers, strong competition from established medtech companies, and reimbursement or pricing pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.26
Dividend Yield
-
Revenue TTM
31.54M
Revenue Per Share
1.15
Gross Profit TTM
16.49M
Debt / Equity
0.03
ROE
3.43%
Net Debt
-15.85M
ROCE
5.45%
Diluted EPS TTM
0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 2.06M 2.67M -4.46M -9.25M 0.42M
Net income 2.06M 2.67M -4.46M -9.66M 23.48M
Selling general administrative 12.42M 7.78M 7.40M 6.96M 4.80M
Selling and marketing expenses - 5.43M 8.17M 6.52M 1.93M
Gross profit 17.47M 18.93M 14.36M 7.49M 9.70M
Reconciled depreciation 0.95M 0.99M 0.97M 1.03M 0.70M
Ebit - 2.15M -4.53M -9.14M 0.84M
Ebitda - 3.14M -3.56M -8.11M 1.54M
Depreciation and amortization - 0.99M 0.97M 1.03M 0.70M
Operating income 1.76M 2.15M -4.53M -9.14M 0.84M
Other operating expenses - 31.17M 31.12M 27.29M 18.72M
Interest expense - - - 0.11M 0.42M
Net interest income 0.44M -0.09M 0.07M -0.11M -0.42M
Income tax expense - - 0.80M 0.41M -23.06M
Total revenue 32.82M 31.17M 26.60M 18.15M 19.56M
Total operating expenses 31.05M 18.93M 18.89M 16.64M 8.86M
Cost of revenue 15.34M 12.24M 12.23M 10.65M 9.86M
Total other income expense net -0.15M 2.67M 0.07M -0.11M -0.42M
Discontinued operations - - - -0.41M 23.06M
Net income from continuing ops 2.06M 2.67M -4.46M -9.25M 0.42M
Net income applicable to common shares - - - -9.66M 23.48M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 36.12M 31.81M 24.90M 30.38M 40.58M
Intangible assets 1.35M 1.44M 1.79M 1.28M 0.90M
Other current assets - 0.69M 0.39M - -
Total liab 5.40M 4.30M 6.11M 6.15M 7.21M
Total stockholder equity 30.73M 27.50M 18.79M 24.23M 33.37M
Deferred long term liab - - - 0.29M 0.38M
Other current liab - 3.32M 0.67M 0.21M 0.41M
Common stock - 51.75M 42.77M 43.84M 44.68M
Capital stock 51.82M 51.75M 42.77M 43.84M 44.68M
Retained earnings -33.64M -35.70M -38.37M -33.91M -24.24M
Other liab - - - 0.05M 0.16M
Other assets - - - 0.29M 0.51M
Cash 17.37M 16.75M 8.79M 14.06M 22.95M
Total current liabilities 3.77M 4.00M 5.19M 4.54M 5.00M
Current deferred revenue - 0.07M 0.08M - -
Net debt - -15.85M -7.23M - -
Short term debt - 0.60M 0.64M - -
Short long term debt total - 0.90M 1.56M - -
Other stockholder equity - 8.32M 11.44M 3.01M 1.11M
Property plant equipment - - - 1.87M 2.11M
Total current assets 31.53M 29.04M 21.29M 27.23M 37.44M
Net tangible assets - - - 23.24M 32.85M
Net receivables 5.84M 3.91M 6.16M 4.73M 6.40M
Inventory 7.40M 7.70M 5.94M 4.97M 4.70M
Accounts payable - - 3.80M 3.72M 4.04M
Accumulated other comprehensive income - 3.13M 2.95M - -
Non currrent assets other - 0.15M 0.14M - 0.14M
Non current assets total 4.59M 2.77M 3.61M 3.15M 3.14M
Capital lease obligations 2.25M 0.90M 1.56M 2.17M 2.59M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -0.28M -1.45M -0.84M -0.28M
Change to liabilities - - - -0.69M 0.02M
Total cashflows from investing activities - - - 0.32M 36.37M
Net borrowings -0.57M -0.48M - -0.59M -7.97M
Total cash from financing activities -0.53M 4.97M -2.16M -2.19M -8.25M
Change to operating activities - - - -1.17M -0.07M
Net income 2.06M 2.67M -4.46M -9.25M 0.42M
Change in cash 0.62M 7.95M -5.27M -8.89M 19.44M
Begin period cash flow 16.75M 8.79M 14.06M 22.95M 3.51M
End period cash flow 17.37M 16.75M 8.79M 14.06M 22.95M
Total cash from operating activities 2.29M 3.47M -3.18M -7.99M 0.62M
Depreciation 0.95M 0.99M 0.97M 1.03M 0.70M
Other cashflows from investing activities - 0.01M - 1.30M 36.55M
Dividends paid - - - 1.60M 0.00M
Change to inventory 0.82M -1.60M -1.04M -0.06M 2.16M
Change to account receivables -1.89M 2.66M -1.47M 1.84M -3.19M
Sale purchase of stock - 0.00M -1.47M -1.73M 0.00M
Other cashflows from financing activities - 5.46M -1.45M 3.33M 0.71M
Change to netincome - - - 0.34M -22.79M
Capital expenditures 0.85M 0.42M 1.32M 1.08M 0.18M
Change in working capital -1.21M -0.28M -0.32M -0.08M -1.08M
Stock based compensation 0.27M 0.41M 0.56M 0.21M 0.16M
Other non cash items 0.06M -0.31M 0.07M 0.11M 0.42M
Free cash flow 1.44M 3.06M -4.50M -9.08M 0.44M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
COV
Covalon Technologies Ltd.
-0.20
4.69%
4.06 65.00 23.81 1.71 2.04 1.21 26.39
OTC
Ocumetics Technology Corp
-
-%
0.40 - - - 41.07 - -79.74
ZEN
ZEN Graphene Solutions Ltd
-0.03
5.66%
0.50 - - 79.84 5.93 77.67 -14.24

Profile*

Covalon Technologies Ltd.

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre- and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers a medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, perioperative dressings, silicone dressings, vascular access line guards, and wound dressings; and surgical, peri-operative, and infection management products. It sells its products directly and through independent distributors under the ColActive, ColActive PLUS, CovaWound, CovaView, CovaClear IV, IV Clear, SurgiClear, MediClear, and VALGuard brands. The company serves health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

1660 Tech Avenue, Mississauga, ON, Canada, L4W 5S7

905-568-8400

Name Title Year Born
Mr. Brian E. Pedlar Pres, CEO & Director NA
Simon Smith Chief Exec. Officer of Covalon Technologies (Europe) Ltd. NA
Gerry Arambula Pres of Covalon Technologies AG Ltd. NA
Dr. Valerio DiTizio Co-Founder, Chief Scientific Officer & VP 1968
Mr. Jason F. Gorel Interim Chief Financial Officer NA
Ms. Elaine Zhang VP of Operations NA
Mr. Ron Hebert Sr. VP of Marketing NA
Mr. Greg Leszczynski VP of HR NA
Mr. Mark Doolittle Sr. VP of Commercial Sales NA
Mr. Hamed Abbasian VP of Bus. Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…